TrialThe Lancet. Respiratory medicine2024

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.

Mengzhao Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.